Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf36341e89aedfd4a9b8e310f70eea44b> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf36341e89aedfd4a9b8e310f70eea44b NCIT_P378 "NCI" @default.
- Bf36341e89aedfd4a9b8e310f70eea44b type Axiom @default.
- Bf36341e89aedfd4a9b8e310f70eea44b annotatedProperty IAO_0000115 @default.
- Bf36341e89aedfd4a9b8e310f70eea44b annotatedSource NCIT_C154277 @default.
- Bf36341e89aedfd4a9b8e310f70eea44b annotatedTarget "A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis." @default.